Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05693922 · ClinicalTrials.gov registry record · NA
Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT05693922 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 30 participants.
The verdict
NCT05693922, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
Investigating whether delta-beta cross-frequency transcranial alternating current stimulation can augment the effects of a single session of behavioral activation in participants with major depressive disorder.
Interventions
- DEVICE Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC
- BEHAVIORAL Single-session behavioral activation
- DEVICE Active sham cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-02-09 |
| Est. Completion | 2024-05-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05693922
The ClinicalTrials.gov registry entry for NCT05693922 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC is the first listed.
NCT05693922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05693922 about?
NCT05693922 is a clinical study titled "Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression". Investigating whether delta-beta cross-frequency transcranial alternating current stimulation can augment the effects of a single session of behavioral activation in participants with major depressive disorder.
What is the current status of trial NCT05693922?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2023-02-09. Estimated completion is 2024-05-22.
What interventions are being tested in trial NCT05693922?
The interventions under investigation include: Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC (DEVICE), Single-session behavioral activation (BEHAVIORAL), Active sham cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC (DEVICE).
Who is sponsoring clinical trial NCT05693922?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.